Publicaciones en las que colabora con Luisa Ugedo Urruela (13)

2020

  1. 6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata

    British Journal of Pharmacology, Vol. 177, Núm. 17, pp. 3957-3974

  2. Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson’s Disease: Exploring Prodromal Biomarkers

    Frontiers in Neuroscience, Vol. 14

2019

  1. Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia

    International Review of Neurobiology (Academic Press Inc.), pp. 259-279

  2. Effects of adult enriched environment on cognition, hippocampal-prefrontal plasticity and NMDAR subunit expression in MK-801-induced schizophrenia model

    European Neuropsychopharmacology, Vol. 29, Núm. 5, pp. 590-600

  3. Nanodelivery of therapeutic agents in Parkinson's disease

    Progress in Brain Research (Elsevier B.V.), pp. 263-279

2018

  1. Correction to: Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson’s Disease (Molecular Neurobiology, (2018), 55, 1, (201-212), 10.1007/s12035-017-0733-x)

    Molecular Neurobiology

  2. Deleterious effects of VEGFR2 and RET inhibition in a preclinical model of Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 201-212

  3. Nanodelivery of cerebrolysin and rearing in enriched environment induce neuroprotective effects in a preclinical rat model of Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 286-299

2017

  1. Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors

    Molecular Neurobiology, Vol. 54, Núm. 10, pp. 7722-7735

2016

  1. Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson's disease

    Journal of Biomedical Nanotechnology, Vol. 12, Núm. 12, pp. 2220-2230

2015

  1. Topographical Distribution of Morphological Changes in a Partial Model of Parkinson’s Disease—Effects of Nanoencapsulated Neurotrophic Factors Administration

    Molecular Neurobiology, Vol. 52, Núm. 2, pp. 846-858

2014

  1. Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease

    International Journal of Nanomedicine, Vol. 9, Núm. 1, pp. 2677-2687

2013

  1. In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 85, Núm. 3 PART B, pp. 1183-1190